Radiommunotherapy and prostate cancer: a promising new therapy in the management of metastatic disease.

The mainstay of treatment for metastatic prostate cancer is androgen deprivation, but unfortunately all patients eventually become resistant to this treatment, developing androgen-independent cancer, with a median time to death of ≈1 year. In addition, taxanebased chemotherapy has met with limited success and is usually associated with significant toxicity. Recent research has suggested that radioimmunotherapy (RIT) using radiolabelled monoclonal antibodies (mAbs) could emerge as a novel and potentially successful treatment for metastatic prostate cancer.